**2019-2020 WSU INSTITUTIONAL REVIEW BOARD PROJECT-SPECIFIC DISCLOSURE OF SIGNIFICANT FINANCIAL INTERESTS (SFI)**

**\*Once all study members complete revised form – not required again at time of Continuing Review/Administrative Update\***

**Purpose:**

This form serves to aid compliance with both the Wright Way Policy “Research Conflict of Interest and Financial Disclosure Policy” and human subject protections.

**Directions:**

This form must be completed for any human subject research project.  **This form is required as part of the initial submission and when an individual is being added as a member of the study team through a separate amendment request or as an amendment request as part of a continuing review/administrative update.** While the task may be delegated, it is ultimately the responsibility of the Principal Investigator (PI) to obtain information regarding significant financial interests (SFIs) from members of the study team who meet the definition of an investigator. Investigator means the Project Director/Principal Investigator and any other person, regardless of title or position, who is responsible for the design, conduct, or reporting of research, or proposing of research, including persons who are subcontractors, collaborators or consultants.

**Definition of “Project Specific” Significant Financial Interest:**

Significant Financial Interest (SFI) means a financial interest consisting of one or more of the following interests of an investigator (and/or of the investigator’s spouse and/or dependent children) that reasonably appears to be related to this research project (i.e., sponsor or product/service being tested):

* With regard to any publicly traded entity, a SFI exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of the disclosure, when aggregated, exceeds $5,000. For purposes of this definition, remuneration includes salary and any payment for services not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship). Equity interests includes any stock, stock option, or other ownership interest, as determined through reference to public prices or other reasonable measures of fair market value.
* With regard to any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the investigator (and/or the investigator’s spouse and/or dependent children) holds any equity interest (e.g., stock, stock option, or other ownership interest); or
* Intellectual property rights and interests (e.g., patents, copyrights), upon receipt of income related to such rights and interests;
* Any reimbursed or sponsored travel related to an investigator’s institutional responsibilities, including that which is paid on behalf of the investigator so that the exact monetary value may not be readily available.

SFI does not include the following types of financial interests:

* Salary, royalties, or other remuneration paid by WSU to the Investigator if the Investigator is currently employed or otherwise appointed by WSU, including intellectual property rights assigned to WSU and agreements to share in royalties related to such rights; income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles.
* Income from seminars, lectures, or teaching engagements sponsored by a federal, state or local agency, an Institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education.
* Income from service on advisory committees or review panels for a federal, state, or local government agency, an Institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education.
* Travel by a PHS-funded Investigator that is reimbursed or sponsored by a federal, state, or local government agency, an Institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education.

**2019-2020 IRB PROJECT-SPECIFIC DISCLOSURE OF SIGNIFICANT FINANCIAL INTERESTS (SFI)**

**IRB Submission Type:  New  Continuation for Transition Only  Modification (adding new Personnel)**

**Study Title**:

**Principal Investigator**:

**Sponsor and/or Manufacturer of Drug, Device, Software, etc.…/ Funding Source(S), if applicable**:

**Product(s) or Service(s) Being Tested**:

**Step 1**: **New Studies:** List all study staff that meet the definition of investigator that will be responsible for the design, conduct and reporting of the research (i.e. PI, Co-I, Study Coordinator, Students, Persons Obtaining Consent). **Modifications:** List only the person(s) being added to the study.

**Step 2:** Please have each study team member review the definition of a SFI found in the instructions for this form before responding, then indicate whether or not he/she or a member of his/her immediate family (spouse, dependent children) have any SFIs related to the sponsor, manufacturer, product etc.. listed above and finally sign to certify response.

**Step 3**: Attach a scanned copy of this completed form to the applicable iRIS submission and maintain a copy of the original in the regulatory binder.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Name,**  **LAST** | **Name, First** | **Role on Study  (PI, Co-I, Consenter, Coordinator)** | **SFI Related\* to this research  exists  (Y/N):** | **If “yes,” has the SFI been reported via InfoEd (Y/N/NA)** | **Signature - I understand that it is my responsibility until study closure to update this form and submit it via InfoED within 30 days of acquiring or discovering a new Significant Financial Interest or a Significant Financial Interest that was not previously disclosed and that is or could appear to be related to this study.** | **Date** |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |

**Note**: tabbing out of the last cell on the right will insert additional rows.